Health · 1 sources covering this

STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect

A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has taken the world by storm.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect
A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has taken the world by storm.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/25e137d5519f830092709dc66c84306b13ea2e1b"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect"></iframe>

STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect

How 1 sources are covering this

STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect

More from Health

Facing Funding Losses, States Call Out Big Businesses With Employees on Medicaid

CDC director nominee Erica Schwartz faces Senate for confirmation hearing

STAT+: Medicare Advantage insurers face new bipartisan scrutiny over AI and care denials

More than 1,600 cases of intestinal illness cyclosporiasis reported in the U.S.

Reader

Trust & legal

Across the network